Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia

Yilmaz, BT; Alioglu, B; Ozyurek, E; Akay, HT; Mercan, S; Ozbek, N

doi:10.1007/s00246-004-0919-7

Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia

Yilmaz B., Alioglu B., Ozyurek E., Akay H., Mercan S., Ozbek N.

PEDIATRIC CARDIOLOGY, vol.26, no.6, pp.843-845, 2005 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 26 Issue: 6
Publication Date: 2005
Doi Number: 10.1007/s00246-004-0919-7
Journal Name: PEDIATRIC CARDIOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.843-845
Keywords: recombinant factor VIIa, cardiopulmonary bypass, cardiac surgery, Glanzmann thrombasthenia, ACTIVATED FACTOR-VII, CONTINUOUS-INFUSION, MANAGEMENT, INHIBITOR, EFFICACY, RFVIIA
Ankara University Affiliated: No

Abstract

Glanzmann thrombasthenia is a rare, hereditary, congenital disorder of platelet function characterized by inappropriate bleeding that is difficult to control. Recombinant activated factor VII (rFVIIa) is a new treatment that is used to stop bleeding and provide surgical support for these patients. This report describes the use of rFVIIa to prevent serious bleeding during and after open-heart surgery in a child with Glanzmann thrombasthenia.